Molybdenum cofactor biosynthesis pathway (MoCo biosynthesis pathway) (MoCo biosynthesis pathway)

The Molybdenum cofactor (MoCo) biosynthesis pathway is a critical metabolic sequence responsible for producing the molybdenum-containing prosthetic group required by essential enzymes such as sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase [1, 2]. This pathway proceeds through several distinct stages, beginning with the conversion of guanosine triphosphate (GTP) into cyclic pyranopterin monophosphate (cPMP) by the MOCS1 enzyme complex, followed by the formation of molybdopterin (MPT) and the final insertion of molybdenum [2, 3]. Genetic mutations in the genes encoding these enzymes, such as MOCS1 (Type A), MOCS2 (Type B), or GPHN (Type C), result in Molybdenum Cofactor Deficiency (MoCD), a devastating autosomal recessive condition [3, 4]. The loss of MoCo leads to the toxic accumulation of sulfite in the central nervous system, causing rapid and severe neurodegeneration, neonatal seizures, and early childhood mortality [1, 5]. Therapeutic strategies focus on bypassing the metabolic block; for instance, fosdenopterin is an FDA-approved substrate replacement therapy that provides exogenous cPMP to patients with MoCD Type A [5, 6]. Monitoring treatment efficacy involves measuring the reduction of urinary S-sulfocysteine, a key biomarker of sulfite toxicity [4, 6].

Other names

MoCo biosynthesis pathwayMolybdenum cofactor metabolic pathwaycPMP-MPT-MoCo pathwayMolybdenum cofactor synthesis

Substrate replacement therapy using a synthetic analog of cyclic pyranopterin monophosphate (cPMP) to restore the biosynthesis of the molybdenum cofactor in patients with MOCS1 deficiency [5, 6].